Follow Up Q&A – Treatment Of Schizophrenia: Focus On Psychopharmacology & Adherence
During this question and answer session, Henry A. Nasrallah, MD and Roger Sommi, PharmD, BCPP, FCCP respond to unanswered questions from their webinar entitled “Treatment Of Schizophrenia: Focus On Psychopharmacology & Adherence”. The full recording of this webinar can be found at the following link: https://psychu.org/treatment-schizophrenia-focus-psychopharmacology-adherence/.
Topics covered in this follow up include:
Use of antipsychotic drug level monitoring in lieu of pharmacogenomic testing
Differences in neuronal tissue loss between antipsychotic generations
Diet and lifestyle modifiers in prevention of neurodegeneration during psychotic episodes
Metabolic considerations …
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.